Leucomycin

Leucomycin (CAS No.: 1392-21-8) is a multi-component 16-membered macrolide antibiotic produced by Streptomyces kitasatoensis, widely utilized as a reference compound in microbiology and drug discovery research focused on ribosome-targeting agents. It exerts its antibacterial activity by binding to the 50S ribosomal subunit, specifically interacting with 23S rRNA, thereby inhibiting bacterial protein synthesis; resistance is commonly associated with mutations at key rRNA residues such as A2058 and A2059. Leucomycin displays broad-spectrum in vitro activity predominantly against Gram-positive organisms including Staphylococcus aureus, Streptococcus species, and Streptococcus pneumoniae, as well as selected Gram-negative bacteria, mycoplasma, and spirochetes, while showing limited efficacy against many enteric Gram-negative species. Reported minimum inhibitory concentrations generally fall within low microgram per milliliter ranges for susceptible strains, indicating potent activity in bacterial growth inhibition assays. Its antibacterial performance is relatively stable across physiological pH conditions and is not significantly diminished in the presence of serum proteins, supporting its utility in complex biological assay systems. In research settings, Leucomycin is commonly applied in studies of translational inhibition, resistance mechanism characterization, and comparative evaluation of macrolide antibiotics, with experimental concentrations or dosing regimens adjusted according to specific in vitro or in vivo model requirements.